Spyre Posts $96.1M Q3 Loss, $1.1B Cash, Runway Into 2H 2029
SYRE has more than doubled off its 52-week low of $21.145.
Summary
Spyre reported a $96.1 million Q3 2026 net loss on sharply higher R&D, but with $1.1 billion in cash plus the $378.0 million October offering it says funding lasts into the second half of 2029.
Key Events · Earnings and Guidance · SYRE
-
Q3 Loss Widens on R&D Surge
Net loss was $96.1 million for Q3 2026 versus $11.2 million a year earlier, with R&D up 97% to $89.2 million on manufacturing, clinical trial and compensation costs.
-
Cash Cushion and Extended Runway
Cash, cash equivalents and marketable securities totaled $1.1 billion at September 30, 2026; counting the October 2026 offering and subsequent ATM sales, management expects funding into the second half of 2029.
-
October Offering Adds $378.0 Million
The company sold 4,735,295 shares at $85.00 per share, including the full over-allotment, for net proceeds of approximately $378.0 million after $24.5 million of costs.
-
SPY072 Rheumatology Program Dropped
The PsA and axSpA sub-studies were well tolerated but missed their primary endpoints, and Spyre does not plan to advance SPY072 in rheumatic diseases.
Analysis · SYRE · Life Sciences
The headline is the widening loss: $96.1 million in Q3 versus $11.2 million a year ago, as R&D spending nearly doubled to $89.2 million on manufacturing and clinical trial costs across the IBD and dermatology programs. What offsets it is balance sheet strength. Cash and securities stood at $1.1 billion on September 30, and with the $378.0 million October offering plus $18.0 million of post-quarter ATM sales, management says operations are funded into the second half of 2029. For a clinical-stage company, that runway removes near-term financing risk and leaves the value case resting on the SKYLINE Part B combination data expected in Q3 2027. The filing also confirms SPY072 failed its PsA and axSpA sub-studies and will not advance in rheumatic diseases, narrowing the pipeline story to IBD and HS.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYRE was trading at $99.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $21.15 to $110.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.